Munn, David H.
Sharma, Madhav D.
Johnson, Theodore S.
Rodriguez, Paulo
Funding for this research was provided by:
National Cancer Institute (R01CA096651, R01CA103320)
Article History
Received: 9 January 2017
Accepted: 2 May 2017
First Online: 9 May 2017
Compliance with ethical standards
:
: David Munn is a consultant to NewLink Genetics Corporation and holds intellectual property in IDO-inhibitors and PTEN-inhibitors. Theodore Johnson receives funding for clinical trials of IDO-inhibitors from NewLink Genetics, Inc. The authors declare that there are no other conflicts of interest.